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Purpose: Oxycodone has affinities for both kappa- and mu-opioid receptors. Therefore, it 
has been used for postoperative analgesia of surgeries in which visceral pain is expected to 
be the main cause of pain. However, there are few studies of the 55:1 potency ratio of 
oxycodone to fentanyl when using it as intravenous patient-controlled analgesia (IV-PCA). 
Thus, we compared the analgesic and adverse effects of IV-PCA using the 55:1 potency ratio 
of oxycodone to fentanyl in patients who underwent robot-assisted laparoscopic gastrectomy.
Patients and Methods: This retrospective study included 100 patients using an automatic PCA 
pump with oxycodone or fentanyl who underwent robot-assisted laparoscopic gastrectomy 
between January and November 2017. All patients were provided with an IV-PCA consisting of 
20 μg/kg of fentanyl or 1.1 mg/kg of oxycodone mixed with 0.9% normal saline solution to a total 
volume of 250 mL, which was infused basally at a rate of 0.1 mL/h with a bolus dose of 1 mL and 
lockout time of 6 min. The primary and secondary endpoints were to evaluate the efficacies of IV- 
PCA using the 55:1 potency ratio of oxycodone to fentanyl on analgesic and adverse effects.
Results: Pain intensity on arrival at the post-anesthesia care unit (PACU; 3.6±1.4 vs 4.4±2.0, 
P=0.031) and additional analgesic requirement within an hour after surgery (including the 
PACU period) (12% vs 37%; P=0.005) were significantly lower in the oxycodone group 
(n=49) than in the fentanyl group (n=51). Regarding adverse effects, the rate of postoperative 
nausea within 1 h after surgery (2% vs 16%; P=0.031) was also significantly lower in the 
oxycodone group than that in the fentanyl group.
Conclusion: Oxycodone-based IV-PCA by dose calculations with a 55:1 potency ratio may 
achieve better analgesia without any significant adverse effects, when using IV-PCA in 
patients undergoing robot-assisted laparoscopic gastrectomy.
Keywords: oxycodone, fentanyl, 55:1 potency ratio, intravenous patient-controlled 
analgesia, robot-assisted laparoscopic gastrectomy
Introduction
For the treatment of stomach cancer, minimally invasive gastrectomy using laparo-
scopic or robotic assistance has become a standard procedure. It has the advantages 
Correspondence: Na Young Kim; Sun 
Joon Bai  
Department of Anesthesiology and Pain 
Medicine, Anesthesia and Pain Research 
Institute, Yonsei University College of 
Medicine, Seoul, Republic of Korea  
Tel +82 2 2228 4435; +82 2 2228 4432  
Email knnyyy@yuhs.ac; sjbae@yuhs.ac
Journal of Pain Research                                                                       Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Journal of Pain Research 2020:13 2197–2204                                                                2197
http://doi.org/10.2147/JPR.S264764 
DovePress © 2020 Koh et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
of reducing postoperative pain, lowering morbidity, and 
speeding up recovery by minimizing skin incisions com-
pared to open surgery.1 Nevertheless, postoperative pain 
remains a problem for patients undergoing robot-assisted 
laparoscopic gastrectomy, and visceral pain is thought to 
be a significant contributor.2
Traditionally, opioid-based intravenous (IV) patient- 
controlled analgesia (PCA) has been the most commonly 
employed modality for relieving moderate to severe acute 
postoperative pain.3 Many studies have been conducted to 
investigate the ideal IV-PCA regimen for maximizing pain 
relief and minimizing side effects simultaneously.3,4 Among 
the opioids used to perform IV-PCA, fentanyl is widely used 
and considered more appropriate and suitable than morphine 
due to its fast onset and short duration of action.4,5 However, 
fentanyl is a potent agonist for mu-opioid receptors but has 
little effect on kappa-opioid receptors, which has been found 
to be one of the major opioid receptors involved in visceral 
pain.6 This mechanism may be one of the reasons why many 
patients complain of diffuse, vague, and poorly defined dis-
comfort, even after IV-PCA has been applied following 
abdominal surgery.6 Oxycodone is a semisynthetic thebaine 
derivative opioid, which has affinity for both mu- and kappa- 
opioid receptors despite its relatively lower affinity for 
kappa-opioid receptors.7 Considering the important role of 
kappa-opioid receptors in the management of visceral pain, it 
is possible that oxycodone may provide more effective 
analgesia than pure mu-opioid receptor agonists in patients 
undergoing major abdominal surgery.8,9 So far, there have 
been studies of several efficacy ratios of oxycodone to fenta-
nyl ranging from 55:1 to 100:1; however, there is still little 
evidence for analgesia and side effects of the 55:1 potency 
ratio of oxycodone to fentanyl during IV-PCA.10–12
Thus, this study aimed to compare the analgesic and 
adverse effects of oxycodone- and fentanyl-based IV-PCA 
in patients who have undergone robot-assisted laparo-




This retrospective study received approval from the 
Institutional Review Board (IRB) and Hospital Research 
Ethics Committee (Yonsei University Health System, 
Seoul, Korea; IRB protocol No. 4-2017-0985) and was con-
ducted in accordance with the ethical standards of the current 
version of the Declaration of Helsinki. The patient records 
and information were anonymized before analysis, which 
involves no more than minimal risk to subject, thus, the 
requirement for informed consent to obtain the medical 
records was exempted by IRB. On IRB approval, the electro-
nic medical records of a total of 119 consecutive patients who 
underwent robot-assisted laparoscopic gastrectomy using an 
automatic PCA pump with oxycodone or fentanyl between 
January and November 2017 were identified at the single 
institution of the university health system.
Anesthesia Protocol
Standardized anesthesia was applied in all patients. After the 
patients arrived in the operating room, their baseline heart 
rate, mean arterial blood pressure, and oxygen saturation 
were monitored. Following the administration of 0.1 mg of 
IV glycopyrrolate as a premedication, anesthesia was 
induced with 1.0–1.5 mg/kg of propofol, 0.6–1.0 mg/kg of 
rocuronium, and 0.05–0.1 μg/kg/min of remifentanil. Age- 
adjusted minimal alveolar concentration end-tidal sevoflur-
ane of 0.6–1.0 and remifentanil of 0.03–0.1 µg/kg/min were 
adjusted according to hemodynamic variables. To maintain 
a constant anesthetic depth, the bispectral index was mon-
itored continuously, the target range of which was between 
40 and 60. At the start of umbilical closure, fentanyl at a dose 
of 1.5 µg/kg or oxycodone at a dose of 0.0825 mg/kg and 
ramosetron at a dose of 0.3 mg were administered to prevent 
postoperative pain and nausea and vomiting. At the end of 
surgery, all patients were provided with an IV-PCA machine 
(Accumate 1100®; Woo Young Medical Co., Ltd., Seoul, 
Korea) consisting of 20 μg/kg of fentanyl or 1.1 mg/kg of 
oxycodone and 0.3 mg of ramosetron (Nasea, Astellas, 
Tokyo, Japan) mixed with 0.9% normal saline solution to 
a total volume of 250 mL, which was infused basally at a rate 
of 0.1 mL/h with a bolus dose of 1 mL and lockout time of 6 
min. The maximum total volume per hour was set up to 
10 mL. After their transfer to the post-anesthesia care unit 
(PACU) after surgery, instructions for the use of the PCA 
machine were provided to all patients, and patients were 
encouraged to push the button whenever they experienced 
the pain. Patients who expressed sustained pain (resting 
numerical rating scale [NRS] score ≥ 4) were intravenously 
administered 50 mg of tridol (Tramadol HCL®, Yuhan Co., 
Seoul, Korea) as additional rescue analgesic.
Data Collection
The data of age, body mass index (BMI), sex, American 
Society of Anesthesiologists (ASA) physical status, and 
coincident diseases (including hypertension, diabetes 
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mellitus, hepatitis, and heart disease) were collected. The 
type of surgery, duration of anesthesia, duration of pneumo-
peritoneum, dose of administered remifentanil, intraopera-
tive fluid input and output, and duration of hospitalization 
were recorded. The active and resting NRSs, number of 
cumulative bolus deliveries, number of cumulative bolus 
attempts, mean blood pressure (MBP), and heart rate (HR) 
were collected from the medical records at PACU, 1, 6, 12, 
24, and 48 h after the surgery. The number of patients who 
received additional rescue analgesics and experienced side 
effects such as nausea, vomiting, dizziness, headache, 
retching, numbness, and chills were assessed during 48 
hours after surgery. And level of sedation was assessed on 
arrival to the PACU.
Statistical Analysis
The primary endpoint was the evaluation of the analgesic 
efficacies of oxycodone- and fentanyl-based IV-PCA in 
patients who underwent robot-assisted laparoscopic gas-
trectomy using a 55:1 potency ratio of oxycodone to 
fentanyl. The secondary endpoints were the influence of 
the 55:1 potency ratio of oxycodone to fentanyl on the 
adverse effects during 48 hours after the surgery.
Comparisons of continuous variables were performed 
using independent two-sample t-tests and are presented as 
mean ± standard deviation. And the comparisons of categori-
cal variables were performed using the chi-square test or 
Fisher`s exact test and are presented as number of patients 
(proportion). Analyses of repeatedly measured variables such 
as the NRS, MBP, HR, number of bolus deliveries, and the 
ratio of deliveries to attempts were performed using a linear 
mixed model. When the interaction of group, time, and group- 
by-time showed statistical significance, a post hoc analysis 
was performed with Bonferroni correction to adjust for multi-
ple comparisons. Logistic and linear regression were per-
formed for the administration of additional rescue analgesic 
and nausea as well as NRS at the PACU. A P value of <0.05 
was regarded as statistically significant. All statistical analyses 
were performed using the SAS version 9.4 software (SAS Inc., 
Cary, NC, USA).
Results
Of 119 patients who underwent robot-assisted laparo-
scopic gastrectomy using an automatic PCA pump with 
oxycodone or fentanyl, 1 patient for whom the surgery 
type was converted to open gastrectomy and 18 patients 
who had incomplete data were excluded. Of the remaining 
100 patients, 49 and 51 patients received oxycodone- and 
fentanyl-based IV-PCA, respectively (Figure 1).
Table 1 shows the demographics and intraoperative vari-
ables of the 100 patients who underwent robot-assisted 
laparoscopic gastrectomy. There were no significant differ-
ences in other variables between the two groups except sex 
and history of hypertension. The numbers of female patients 
and those with a history of hypertension were significantly 
higher in the fentanyl group than those in the oxycodone 
group. The pain intensity on arrival at the PACU was sig-
nificantly lower in the oxycodone group than in the fentanyl 
group (3.6 ± 1.4 vs 4.4 ± 2.0, P = 0.031). However, from the 
discharge of the PACU until 48 h after surgery, there were no 
significant differences in NRSs between the two groups 
(Figure 2). In addition, there was no significant difference 
between the numbers of patients who reported NRS≥4 and 
NRS<4 at any time points.
Significant intergroup differences in the cumulative 
bolus deliveries were observed over time in the linear 
mixed model analysis (P Group × Time < 0.001) (Figure 3A). 
Patients in the oxycodone group had a significantly lower 
number of bolus deliveries than those in the fentanyl group 
at 24 and 48 h after surgery (Bonferroni corrected P = 0.009 
and 0.003, respectively). However, no significant inter-
group differences in the cumulative bolus attempts and 
deliveries/attempts ratio were noted throughout all time 
points after surgery (Figure 3B and C).
Furthermore, the number of patients who required addi-
tional rescue analgesics and experienced postoperative nau-
sea at the PACU was significantly lower in the oxycodone 
group than that in the fentanyl group (rescue analgesics, 
12% vs 37%; P = 0.005, nausea, 2% vs 16%; P = 0.031, 
Figure 1 Consort diagram of patients. 
Abbreviation: IV-PCA, intravenous patient-controlled analgesia.
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respectively). However, after discharge from the PACU, no 
significant differences were observed between the two 
groups (Table 2). In multivariate regression, the fentanyl 
group had a significantly higher risk of additional rescue 
analgesic requirements at the PACU compared to the oxy-
codone group (odds ratio [OR] = 4.68; 95% confidence 
interval [CI], 1.53–14.37, P = 0.007). However, the risk of 
nausea in the PACU was no longer significant (Table 3). In 
addition, the NRS in the PACU remained significantly 
higher in the fentanyl group than that in the oxycodone 
group even after multivariate analysis (Beta, 1.017; 
Standard error, 0.374, P = 0.008).
Oher postoperative adverse effects such as dizziness, 
headache, retching, numbness, and chills were not statisti-
cally different between the two groups. Also, there were 
no significant differences in sedation level on arrival to the 
PACU (Table 4). No differences in MBP and HR were 
observed between the two groups, as shown in Figure 4.
Discussion
We conducted this retrospective study based on a review 
of medical records to compare the analgesic and adverse 
effects of oxycodone- and fentanyl-based IV-PCA in 
patients who underwent robot-assisted laparoscopic gas-
trectomy using a 55:1 potency ratio of oxycodone to 
fentanyl. According to the results of this study, IV-PCA 
based on oxycodone showed better analgesia and lower 
postoperative nausea than that based on fentanyl during 
early postoperative period.
Several opioids have been used for IV-PCA. Among 
the opioids, morphine is well known for its side effects 
such as sedation, nausea/vomiting, pruritis, and respiratory 
Table 1 Demographics and Intraoperative Parameters
Oxycodone Group (n = 49) Fentanyl Group (n = 51) P value
Age, years 53 ± 10 55 ± 11 0.273
BMI 23.6 ± 2.6 23.0 ± 2.9 0.270
Male sex 30 (61%) 17 (33%) 0.005*
ASA physical status, I/II/III 24/22/3 22/26/3 0.897
Comorbidities
Hypertension 11 (23%) 21 (41%) 0.045*
Diabetes mellitus 8 (16%) 6 (12%) 0.511
Hepatitis 0 (0%) 1 (2%) >0.999
Heart disease 2 (4%) 1 (2%) 0.614
Subtotal/Total 35/14 42/9 0.194
Anesthesia time, min 235.0 ± 61.0 224.4 ± 61.6 0.391
Pneumoperitoneum time, min 142.9 ± 53.7 132.9 ± 61.6 0.391
Total remifentanil amounts, µg 769.4 ± 276.3 719.6 ± 282.1 0.375
Fluid intake, mL 1332 ± 400 1331 ± 584 0.998
Blood loss, mL 42 ± 38 59 ± 94 0.237
Urine output, mL 176 ± 104 208 ± 122 0.173
Hospital days 5.5 ± 1.5 5.7 ± 3.0 0.744
Notes: Data are presented as mean ± standard deviation or number of patients (proportion). *P <0.05. 
Abbreviations: BMI, body mass index; ASA, American Society of Anesthesiologist; Subtotal, subtotal gastrectomy; Total, total gastrectomy.
Figure 2 Changes in resting (A) and active (B) pain intensity until 48 hours after surgery. 
Abbreviation: NRS, numeric rating score.
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depression. Therefore, fentanyl has been more widely used 
for IV-PCA.13 However, another hydrophilic opioid, oxy-
codone, has been introduced. This opioid showed lower 
sedation than morphine, and the incidence of other side 
effects were comparable with that of fentanyl.14 For this 
reason, attempts have been made to use oxycodone in IV- 
PCA.
Morphine and oxycodone have been reported to have 
analgesic potencies of 1:1–1.5 when administered 
intravenously.15–17 Thus, a number of studies have been 
conducted with potency ratios of oxycodone to fentanyl of 
75–100:1.8,13,18,19 In these studies, during the postoperative 
period, oxycodone produced similar or better results in terms 
of analgesia than fentanyl while the incidences of adverse 
effects were higher. However, in terms of analgesic effects, 
opioids do not have a ceiling effect, and more effective 
analgesia can be achieved by higher doses. However, higher 
doses of opioids are associated with adverse effects such as 
respiratory depression, sedation, and nausea/vomiting. 
Therefore, an important aspect in the use of opioids is to 
use as low of a dose as possible to maximize analgesic effects 
while minimizing side effects.
Therefore, studies have been conducted using a potency 
ratio lower than 1:75 for the purpose of postoperative 
analgesia.10,12 Despite the lower doses used in these studies, 
oxycodone showed similar analgesic potency compared to 
that of fentanyl. However, in the present study with 
a potency ratio of 55:1, oxycodone was found to have 
even superior analgesic effects in the PACU than those of 
fentanyl. This study was performed with patients who 
underwent robot-assisted laparoscopic gastrectomy, which 
can be performed with less skin or muscle damage com-
pared to open repair.1 In such surgeries, visceral pain may 
be a very important contributor to postoperative pain. 
Kappa-opioid receptor affinity may be associated with bet-
ter analgesia in these surgeries.
Oxycodone has similar properties to those of morphine in 
terms of hydrophilicity and protein binding capacity.20 
However, oxycodone has higher affinities for kappa and 
delta receptors than morphine.7,21 Kappa-opioid receptors 
are known to have a distribution and function that differenti-
ate them from the most well-known mu-opioid receptors. 
Kappa-opioid receptors are widely distributed in the periph-
eral sensory neurons, as well as in the brain and spinal 
cord.17,22 It has been reported that they may be associated 
with effective control of visceral pain.17,23 This mechanism 
may explain the result of sufficient analgesia with a lower 
dose of oxycodone when visceral pain may play a major role 
in postoperative pain, as observed in this study. In this study, 
fewer patients in the oxycodone group required rescue 
analgesics in the early postoperative period even after multi-
variate analysis. In addition, patients in the oxycodone group 
had a significantly lower number of bolus deliveries than 
those in the fentanyl group at 24 and 48 h after surgery, 
which indicates that the usage of oxycodone at a 55:1 
potency ratio may have increased the efficacy. Therefore, 
the results of the present study suggest that oxycodone- 
based IV-PCA with a 55:1 potency ratio used in these sur-
geries can provide sufficient analgesia both in the early and 
late postoperative periods. However, further investigation is 
required to better clarify these observations.
Figure 3 Number of cumulative bolus deliveries (A), cumulative bolus attempts 
(B), and ratio of deliveries to attempts (C). *Bonferroni-corrected P < 0.05 
compared with the fentanyl group.
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Oxycodone has been reported to be associated with 
a higher nausea incidence than fentanyl.8,19,24 Even at a 60:1 
potency ratio of oxycodone to fentanyl, Park et al reported 
a higher incidence of nausea in the oxycodone group.12 In 
contrast, Jung et al reported that there is no difference in the 
incidence rate of nausea between groups at the 55:1 potency 
ratio.10 Consistent with previous reports, multivariate analysis 
in the current study revealed no significant difference in the 
incidence rate of nausea between the two groups. In addition, 
oxycodone has been reported to be associated with a higher 
incidence of other side effects than fentanyl, such as dizziness, 
headache, and sedation.12,14,25 In particular, Park et al reported 
significantly higher rates of dizziness even at a potency ratio of 
60:1.8,12 However, according to the results of this study, 
Table 2 Number of Patients Who Required Additional Rescue 










PACU 6 (12%) 19 (37%) 0.005*
1–6 h 30 (61%) 36 (71%) 0.400
6–12 h 29 (59%) 25 (49%) 0.324
12–24 h 34 (69%) 28 (55%) 0.154
24–48 h 23 (47%) 26 (51%) 0.659
Nausea
PACU 1 (2%) 8 (16%) 0.031*
1–6 h 7 (14%) 13 (26%) 0.213
6–12 h 14 (29%) 15 (29%) >0.999
12–24 h 12 (25%) 10 (20%) 0.633
24–48 h 2 (4%) 4 (8%) 0.678
Vomiting
PACU – –
1–6 h 1 (2%) 3 (6%) 0.618
6–12 h 2 (4%) 6 (12%) 0.269
12–24 h – 1 (2%) >0.999
24–48 h – –
Notes: Data are presented as number of patients (proportion). *P <0.05. 
Abbreviation: PONV, postoperative nausea and vomiting.
Table 3 Multivariate Regression Analysis of the Number of 
Patients Requiring Additional Rescue Analgesics and Who 




OR (95% CI) P value OR (95% CI) P value
Group
Oxycodone 1 1
Fentanyl 4.68(1.53–14.37) 0.007* 6.38 (0.73–55.70) 0.094
Sex
Male 1 1




Yes 0.56 (0.18–1.74) 0.318 1.88 (0.40–8.83) 0.425
Note: *P <0.05. 
Abbreviations: OR, odds ratio; CI, confidence interval; HTN, hypertension; 
PACU, post-anesthetic care unit.








Dizziness 16 (33%) 13 (26%) 0.511
Headache 2 (4%) 0 (0%) 0.238
Retching – 1 (2%) >0.999
Numbness – 1 (2%) >0.999
Chills – 1 (2%) >0.999
Level of sedation at 
PACU, 0/1/2/3/4
0/7/42/0/0 0/4/47/0/0 0.303
Notes: Data are presented as median (interquartile range) or number of patients 
(proportion). Level of sedation; 0 = fully awake, 1= drowsy/closed eyes, 2 = asleep/ 
easily aroused with light tactile stimulation or a simple verbal command, 3 = asleep/ 
aroused only by strong physical stimulation, and 4 = unarousable.
Figure 4 Mean blood pressure (A) and heart rate during 48 h after surgery (B). 
Abbreviation: PACU, post-anesthesia care unit.
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oxycodone using a potency ratio of 55:1 would not increase the 
incidence of other side effects compared with fentanyl.
There are some limitations to this study. The retrospective 
design made it difficult to thoroughly control the variables. 
Although we tried to use standardized anesthesia and pain 
control methods in our institution, additional factors might 
have affected the results, such as the bolus dose administered 
at the end of surgery and the influence of additional rescue 
analgesics on the adverse effects. In addition, because some 
quantitative indicators were not measured, such as the degree 
of nausea in scales, it was difficult to perform a more in-depth 
analysis. The power may have been increased if the sample 
size had been larger. Additional, larger-scale studies with other 
designs are warranted for better clarification.
Conclusions
Oxycodone-based IV-PCA by dose calculations with 
a 55:1 potency ratio may achieve better analgesia without 
any significant adverse effects, when using IV-PCA in 
patients undergoing robot-assisted laparoscopic gastrect-
omy. Further, larger-scale studies with other designs are 
needed for better clarification.
Abbreviations
ASA, American Society of Anesthesiologists; BMI, body 
mass index; CI, confidence interval; HR, heart rate; IV, 
intravenous; IV-PCA, intravenous patient-controlled 
analgesia; MBP, mean blood pressure; NRS, numerical 
rating scale; OR, odds ratio; PACU, post-anesthesia care 
unit; PCA, patient-controlled analgesia.
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